Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

299 recalls, newest first

Class II · Moderate risk

BD ChloraPrep Hi-Lite Orange 2% w/v chlorhexidine gluconate

Lack of Assurance of Sterility: Product is being recalled because at labeled storage conditions of 30*C/75% Relative Humidity, there is the potential for growth of Aspergillus penicillioides, a type of fungus, resulting in a breach of the package integrity.

Terminated Sterility / contamination CareFusion 213, LLC NDC 54365-400-33 D-0348-2021
Class II · Moderate risk

BD ChloraPrep Clear

Lack of Assurance of Sterility: Product is being recalled because at labeled storage conditions of 30*C/75% Relative Humidity, there is the potential for growth of Aspergillus penicillioides, a type of fungus, resulting in a breach of the package integrity.

Terminated Sterility / contamination CareFusion 213, LLC NDC 54365-400-32 D-0347-2021
Class I · High risk

BD ChloraPrep Clear

Non-sterility.Product is being recalled because at labeled storage conditions of 30*C/75% Relative Humidity, growth of Aspergillus penicillioides, a type of fungus, resulted in a breach of the package integrity.

Terminated Sterility / contamination CareFusion 213, LLC NDC 54365-400-32 D-0343-2021
Class II · Moderate risk

Phenylephrine HCl Injection

Lack of Assurance of Sterility: customer complaints of loose crimped vial overseals which may result in a non-sterile product.

Terminated Sterility / contamination Sagent Pharmaceuticals Inc D-0305-2021
Class II · Moderate risk

Leucovorin Calcium for Injection

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-5145-01 D-0285-2021
Class II · Moderate risk

MethyIPREDNISolone Acetate Injectable Suspension USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-0063-01 D-0284-2021
Class II · Moderate risk

MethyIPREDNISolone Acetate Injectable Suspension USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-0043-01 D-0283-2021
Class II · Moderate risk

MethyIPREDNISolone Acetate Injectable Suspension USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-0045-01 D-0282-2021
Class II · Moderate risk

MethyIPREDNISolone Acetate Injectable Suspension USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-0051-01 D-0281-2021
Class II · Moderate risk

Epoprostenol Sodium for Injection

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-1995-01 D-0280-2021
Class II · Moderate risk

Vecuronium Bromide for Injection

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-2914-01 D-0279-2021
Class II · Moderate risk

Toposar (etoposide injection USP)

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-5657-01 D-0278-2021
Class II · Moderate risk

Metoclopramide Injection USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-4502-01 D-0277-2021
Class II · Moderate risk

Leucovorin Calcium for Injection

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-5140-01 D-0276-2021
Class II · Moderate risk

MethyIPREDNISolone Acetate Injectable Suspension USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-0031-01 D-0275-2021
Class II · Moderate risk

Epoprostenol Sodium for Injection

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-1985-01 D-0274-2021
Class II · Moderate risk

Sterile Diluent for Epoprostenol Sodium for Injection

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-9258-01 D-0273-2021
Class II · Moderate risk

Desmopressin Acetate Injection USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-5051-01 D-0272-2021
Class II · Moderate risk

Dacarbazine for Injection USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-5075-01 D-0271-2021

Recalls by year